KYMERA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
KYMERA THERAPEUTICS, INC. (KYMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.12% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.12%, a 3.78% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.70%, a 7.50% decline year-over-year.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.81%, a 3.25% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 3.97%, a 6.59% decline year-over-year.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 2.44% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.10%, a 0.00% change from fiscal 2023.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 95.24% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.10%, a 133.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.12% 10-Q · filed 2026-08-05 | 3.77% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 3.70% 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | 4.00% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 3.81% 10-Q · filed 2025-11-04 | 3.98% 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 3.97% 10-Q · filed 2026-08-05 | 3.99% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.00% 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | 4.10% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 3.69% 10-Q · filed 2025-11-04 | 4.12% 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 4.25% 10-Q · filed 2025-08-11 | 4.14% 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 4.13% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 4.10% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.14% 10-Q · filed 2024-10-31 | 4.06% 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | 3.71% 10-Q · filed 2024-08-07 | 4.06% 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 4.14% 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | 2.10% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 3.01% 10-Q · filed 2023-11-02 | 1.95% 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-03 | 1.87% 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | 1.59% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 0.90% 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 0.91% 10-Q · filed 2022-11-03 | 0.90% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 1.05% 10-Q · filed 2022-08-09 | 0.90% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 0.84% 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | 0.50% 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 0.35% 10-Q · filed 2021-11-10 | 0.51% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.41% 10-Q · filed 2021-08-06 | 0.65% 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | 1.68% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 1.83% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 1.43% 10-Q · filed 2020-11-05 | 1.89% 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |